TITLE

EPITAN ACQUIRES THREE DERMATOLOGY PRODUCTS

PUB. DATE
September 2004
SOURCE
Worldwide Biotech;Sep2004, Vol. 16 Issue 9, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the acquisition of three dermatological products by pharmaceutical company EpiTan Ltd., as part of its strategy to develop a specialty pharmaceutical business focused on dermatology. Information on the acquired products; Other acquisitions and in-licensing product opportunities of the company; Information on the firm's leading dermatology product, Melanotan, which is set to be launched in late 2006 or early 2007.
ACCESSION #
14267594

 

Related Articles

  • Happy Window Shopping. Levine, Norman // Dermatology Times;Dec2002, Vol. 23 Issue 12, p4 

    Recommends possible solutions to the pricing problem of dermatologic agents. Limiting development cost of important technologies; Estimating drug costs before beginning development efforts.

  • Direct-to-Consumer Prescription Drug Advertising, 1989-1998. Bell, Robert A.; Kravitz, Richard L.; Wilkes, Michael S. // Journal of Family Practice;Apr2000, Vol. 49 Issue 4, p329 

    BACKGROUND • We conducted a content analysis of consumer-targeted prescription drug advertisements to explore trends in prevalence, shifts in the medical conditions for which drugs are promoted, reliance on financial and nonmonetary inducements, and appeals used to attract public interest,...

  • TARO PHARMACEUTICALS ACQUIRES TIAMOL FOR U.S./CANADA.  // Worldwide Biotech;Sep2000, Vol. 12. Issue 9, p4 

    Reports the market approval received by Tiamol, a dermatologic drug frok Taro Pharmaceutical Industries Inc., in the United States and Canada.

  • iPledge for isotretinoin: One drug, one system, many companies. Posey, L. Michael // Pharmacy Today;Oct2005, Vol. 11 Issue 10, p20 

    Focuses on the introduction of iPledge, a national computerized risk management program for isotretinoin distribution and use, in the U.S. Elements of the program; Need for pharmaceutical firms to register with the program; Limitations of the program.

  • counterirritant.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p536 

    An encyclopedia entry for "counterirritant," which refers to an agent like a mustard plaster that is applied locally to produce an inflammatory reaction for the purpose of affecting some other part, usually near or underlying the surface irritated, is presented.

  • Important Drug Interactions in Dermatology. Roos, T.C.; Merk, H.F. // Drugs;Feb2000, Vol. 59 Issue 2, p181 

    Drug interactions can occur at any step from absorption to elimination of a drug, and can induce adverse as well as beneficial effects. Since systemic drugs are increasingly available and important in the treatment of dermatological diseases, a variety of possible interactions between...

  • Anti-aging topicals: More bark than bite. Nash, Karen // Dermatology Times;Oct97, Vol. 18 Issue 10, p28 

    Evaluates the efficacy of anti-aging dermatologic topical agents. Benefits of anti-aging products; Recommendations on the use of product combinations for better results; Comparisons on the efficacy of tretinoin treatment with other anti-aging products.

  • First Rx topical for vasomotor symptoms.  // Drug Topics;10/20/2003, Vol. 147 Issue 20, p6 

    Reports on the U.S. Food and Drug Administration's approval for a topical treatment for vasomotor symptoms in menopausal women.

  • The right acne drug for you.  // Redbook;Dec97, Vol. 190 Issue 2, p28 

    Presents prescription drugs for treating acne. Comparison of the four drugs; Indications of each.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics